- Albania / Albania
- Austria / Österreich
- Bosnia and Herzegovina / Босна и Херцеговина
- Bulgaria / България
- Croatia / Hrvatska
- Czech Republic & Slovakia / Česká republika & Slovensko
- Finland / Suomi
- France / France
- Germany / Deutschland
- Greece / ΕΛΛΑΔΑ
- Italy / Italia
- Netherlands / Nederland
- Nordic / Nordic
- Poland / Polska
- Portugal / Portugal
- Romania & Moldova / România & Moldova
- Slovenia / Slovenija
- Serbia & Montenegro / Србија и Црна Гора
- Spain / España
- Switzerland / Schweiz
- Turkey / Türkiye
- UK & Ireland / UK & Ireland
DUBAI, UAE: Scientifically designed from the ground up for long-term stability and tissue preservation—essential factors that contribute to the lasting aesthetics that clinicians and patients demand—NobelActive by Nobel Biocare is backed by a decade of clinical scrutiny and proven performance. That is the basis for NobelActive’s success, the Swiss company said.
According to Nobel Biocare, the development of NobelActive was a breakthrough in implant design, and it is now one of the most prominent solutions in the company’s extensive range of implants. The product has been proved by evidence based on 42 clinical studies that have evaluated over 14,300 NobelActive implants in over 2,600 patients. This current count only includes studies that examined a minimum of ten NobelActive implants followed up for more than one year.
Studies have shown that NobelActive preserves the critical marginal bone and soft tissue over time for natural-looking aesthetics. Its back-tapered collar—together with a strong conical connection and built-in platform shifting—can aid crestal bone and soft-tissue preservation. In the aesthetic zone, the solution for narrow spaces, NobelActive 3.0, allows clinicians to restore maxillary lateral incisors and mandibular lateral and central incisors immediately, with a high survival rate, good aesthetics and bone maintenance. Other peer-reviewed studies have found that NobelActive performed predictably and effectively in fresh extraction sockets in the maxillary aesthetic zone, and papillary size significantly improved during the first year and from implant insertion until three and five years thereafter.
Given such applicability, NobelActive’s mean implant survival rate of 98.5 per cent—in studies with up to 5 years of follow-up—adds to the satisfaction of both patients and clinicians.
The unique implant design ensures primary stability, even in soft bone and fresh extraction sockets. Important research findings include low bone remodelling in the healing phase, followed by stable or increasing bone levels, as well as excellent hard- and soft-tissue outcomes and a 100 per cent survival rate after up to 6.7 years of function. Furthermore, NobelActive has been found to be a reliable implant for challenging cases, such as severely atrophic maxillae.
The reverse-cutting flutes with drilling blades on the apex enable the adjustment of the implant position during placement for an optimised restoration orientation, particularly in extraction sites. Furthermore, the internal conical connection with hexagonal interlocking offers high mechanical strength.
In terms of aesthetics, self-esteem, speech, sense and function, NobelActive implants have proved satisfying to patients. They have given high marks regarding their use, from pre-treatment to prosthetic delivery, all the way through three-year follow-up.
AEEDC 2019 attendees who are interested in finding out more about NobelActive, or other products from the company’s extensive portfolio, are invited to join its booth 6F06.